ID   ETK-1
AC   CVCL_1206
SY   ETK1
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03151925
DR   CCLE; ETK1_BILIARY_TRACT
DR   Cell_Model_Passport; SIDM00276
DR   ChEMBL-Cells; CHEMBL3308831
DR   ChEMBL-Targets; CHEMBL2366116
DR   Cosmic; 906861
DR   Cosmic-CLP; 906861
DR   DepMap; ACH-002237
DR   GDSC; 906861
DR   GEO; GSM1669779
DR   LINCS_LDP; LCL-1789
DR   PharmacoDB; ETK1_348_2019
DR   RCB; RCB1289
DR   Wikidata; Q54832847
RX   CelloPub=CLPUB00275;
RX   PubMed=9252136;
RX   PubMed=10761710;
RX   PubMed=16643607;
RX   PubMed=20143388;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a SSP-25 derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from the ascitic fluid of a 61 year old woman patient with sarcomatoid cholangiocarcinoma.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00196.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=3.1%; Native American=0%; East Asian, North=74.88%; East Asian, South=17.31%; South Asian=0%; European, North=0.67%; European, South=4.05% (PubMed=30894373).
CC   Discontinued: RCB; RCB1289; true.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 10,12
ST   D5S818: 10
ST   D7S820: 11
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_4902 ! SSP-25
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 25
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=9252136; DOI=10.1002/hep.510260206;
RA   Enjoji M., Nakashima M., Honda M., Sakai H., Nawata H.;
RT   "Hepatocytic phenotypes induced in sarcomatous cholangiocarcinoma
RT   cells treated with 5-azacytidine.";
RL   Hepatology 26:288-294(1997).
//
RX   PubMed=10761710; DOI=10.1111/j.1349-7006.2000.tb00935.x;
RA   Enjoji M., Nakashima M., Nakamuta M., Nawata H.;
RT   "Transforming growth factor-alpha induces the differentiation of
RT   sarcomatoid cholangiocarcinoma cells.";
RL   Jpn. J. Cancer Res. 91:223-230(2000).
//
RX   PubMed=16643607; DOI=10.1111/j.1749-0774.2005.00007.x;
RA   Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T.,
RA   Obata Y., Nakamura Y.;
RT   "Essential role for gene profiling analysis in the authentication of
RT   human cell lines.";
RL   Hum. Cell 19:43-48(2006).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//